Immunotherapy of colorectal cancer: new perspectives after a long path

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Ferlay J, Bray F, Pisani P et al. GLOBOCAN 2000. Cancer incidence mortality and prevalence worldwide, IARC, cancer base No 5, version 1.0. IARC Press, Lyon, France (2001).
  Google Scholar
• 2 Meyerhardt JA. Systemic therapy for colorectal cancer. N. Engl. J. Med. 352(5), 476–487 (2005).
  Medline CASGoogle Scholar
• 3 Eng C. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist 15(1), 73–84 (2010).
  Medline CASGoogle Scholar
• 4 Seetharamu N, Budman DR, Sullivan KM. Immune checkpoint inhibitors in lung cancer: past, present and future. Future Oncol. 12(9), 1151–1163 (2016).
  CASGoogle Scholar
• 5 Hirayama M, Nishimura Y. The present status and future prospects of peptide-based cancer vaccines. Int. Immunol. 28(7), 319–328 (2016). • An overview defining the role of peptide-based active immunotherapy.
  Medline CASGoogle Scholar
• 6 Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 133(5), 775–787 (2008).
  Medline CASGoogle Scholar
• 7 Bedoui S, Heath WR, Mueller SN. CD4(+) T-cell help amplifies innate signals for primary CD8(+) T-cell immunity. Immunol. Rev. 272(1), 52–64 (2016).
  Medline CASGoogle Scholar
• 8 Peace DJ, Chen W, Nelson H, Cheever MA. T cell recognition of transforming proteins encoded by mutated ras protooncogenes. J. Immunol. 146, 2059–2065 (1991).
  Medline CASGoogle Scholar
• 9 Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLAA2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152, 163–175 (1994).
  Medline CASGoogle Scholar
• 10 Chen L, Linsley PS, Hellström KE. Costimulation of T cells for tumor immunity. Immunol. Today 14(10), 483–486 (1993).
  Medline CASGoogle Scholar
• 11 Esensten JH, Helou YA, Chopra G et al. CD28 costimulation: from mechanism to therapy. Immunity 44(5), 973–988 (2016).
  Medline CASGoogle Scholar
• 12 Harris JE, Ryan L, Hoover HC Jr et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol. 18(1), 148–157 (2000).
  Medline CASGoogle Scholar
• 13 Hanna MG Jr, Hoover HC Jr, Vermorken JB et al. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized Phase III trials show promise. Vaccine 19(17–19), 2576–2582 (2001).
  MedlineGoogle Scholar
• 14 Rao B, Han M, Wang L et al. Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. J. Transl. Med. 9, 17 (2011). • A meta-analysis defining the role of active immunotherapy in colorectal cancer (CRC) patients with minimal disease.
  MedlineGoogle Scholar
• 15 De Remigis A, de Gruijl TD, Uram JN et al. Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. Int. J. Cancer. 136(1), 127–137 (2015).
  Medline CASGoogle Scholar
• 16 Shevtsov M, Multhoff G. Heat shock protein-peptide and HSP-based immunotherapies for treatment of cancer. Front. Immunol. 7, 171 (2016).
  MedlineGoogle Scholar
• 17 Mazzaferro V, Coppa J, Carrabba MG et al. Vaccination with autologous tumor derived heat shock proten gs96 after liver resection for metastatic colorectal cancer. Clin. Cancer. Res. 9, 3235–3245 (2003).
  Medline CASGoogle Scholar
• 18 Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology 5(1), e1115641 (2015).
  MedlineGoogle Scholar
• 19 Ockert D, Schirrmacher V, Beck N et al. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin. Cancer Res. 2(1), 21–28 (1996).
  Medline CASGoogle Scholar
• 20 Moingeon P. Recombinant cancer vaccines based on viral vectors. Dev. Biol. (Basel). 116, 117–122; discussion 133–143 (2004).
  Medline CASGoogle Scholar
• 21 Marshall J. Carcinoembryonic antigen-based vaccines. Semin. Oncol. 30(3 Suppl. 8), 30–36 (2003).
  Medline CASGoogle Scholar
• 22 Xiang B, Snook AE, Magee MS, Waldman SA. Colorectal cancer immunotherapy. Disc. Med. 15(84), 301–308 (2013). • An overview defining the role of active immunotherapy in metastatic (m)CRC patients.
  MedlineGoogle Scholar
• 23 Kaufman HL, Lenz HJ, Marshall J et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin. Cancer Res. 14(15), 4843–4849 (2008).
  Medline CASGoogle Scholar
• 24 Marshall JL, Gulley JL, Arlen PM et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 23(4), 720–731 (2005).
  Medline CASGoogle Scholar
• 25 Brown ME, Miao H, McKee MD. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Cancer Res. 11(16), 5993–6001 (2005).
  Google Scholar
• 26 Weihrauch MR, Ansén S, Jurkiewicz E et al. Recognition of carcinoembryonic antigen peptide and heteroclitic peptide by peripheral blood T lymphocytes. J. Immunother. 30(3), 350–358 (2007).
  MedlineGoogle Scholar
• 27 Morse MA, Niedzwiecki D, Marshall JL et al. A randomized Phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann. Surg. 258(6), 879–886 (2013).
  MedlineGoogle Scholar
• 28 Snool A, Baybutt T, Mastrangelo M et al. A Phase I study of AD5-GUY2C-PADRE in stage I and II colon cancer patients. J. Immunother. Cancer 3(Suppl. 2), P450 (2015).
  Google Scholar
• 29 Correale P, Sabatino M, Cusi MG et al. In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase. J. Chemother. 13(5), 519–526 (2001).
  Medline CASGoogle Scholar
• 30 Correale P, Del Vecchio MT, Di Genova G et al. 5-Fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J. Natl Cancer Inst. 97(19), 1437–1445 (2005). •• A study defining the preclinical rationale for thymidylate synthase poly-epitope peptide (TSPP) vaccination alone or in combination with chemotherapy in cancer patients.
  Medline CASGoogle Scholar
• 31 Correale P, Del Vecchio MT, M La Placa M et al. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide specific CTLs. J. Immunother. 31, 132–147 (2008). • A study defining the preclinical rationale for TSPP vaccination in combination with chemoimmunotherapy in mCRC patients.
  Medline CASGoogle Scholar
• 32 Cusi MG, Botta C, Pastina P et al. Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients. Cancer Immunol. Immunother. 64(9), 1159–1173 (2015). • A study defining the safety and immune-biological activity of TSPP peptide vaccination in advanced cancer patients.
  Medline CASGoogle Scholar
• 33 Correale P, Botta C, Martino EC et al. Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients. Oncoimmunology 5(4), e1101205 (2015). •• A study defining the safety and immune-biological activity of TSPP peptide in combination with chemoimmunotherapy in mCRC patients.
  MedlineGoogle Scholar
• 34 Zhang Z, Wang LP, Zhao XL et al. Pseudomonas aeruginosa injection enhanced antitumor cytotoxicity of cytokine-induced killer cells derived from cord blood. Biomed. Pharmacother. 68(8), 1057–1063 (2014).
  Medline CASGoogle Scholar
• 35 de Groot CA, Marcon L, Bishop EA et al. HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine. 23(17–18), 2379–2387 (2005).
  MedlineGoogle Scholar
• 36 Schulze T, Kemmner W, Weitz J et al. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol. Immunother. 58(1), 61–69 (2009).
  Medline CASGoogle Scholar
• 37 Sato Y, Maeda Y, Shomura H et al. A Phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br. J. Cancer 90(7), 1334–1342 (2004).
  Medline CASGoogle Scholar
• 38 Rahma OE, Hamilton JM, Wojtowicz M et al. The immunological and clinical effects of mutated raspeptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J. Transl. Med. 12, 55 (2014).
  MedlineGoogle Scholar
• 39 Barth RJ Jr, Fisher DA, Wallace PK et al. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine incolorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin. Cancer Res. 16(22), 5548–5556 (2010).
  Medline CASGoogle Scholar
• 40 Lesterhuis WJ, De Vries IJ, Schreibelt G et al. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEAmRNA for vaccination of colorectal cancer patients. Anticancer Res. 30(12), 5091–5097 (2010).
  MedlineGoogle Scholar
• 41 Zhu H, Yang X, Li J et al. Immune response, safety, and survival and qualityof life outcomes for advanced colorectal cancer patients treated with dendriticcell vaccine and cytokine-induced killer cell therapy. BioMedRes. Intl 2014, 603871 (2014).
  MedlineGoogle Scholar
• 42 Gao D, Li C, Xie X et al. Autologous tumor lysate-pulsed dendritic cell immunotherapy withcytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PloS ONE 9(4), e93886 (2014).
  MedlineGoogle Scholar
• 43 Harrop R, Connolly N, Redchenko I et al. Vaccination of colorectal cancerpatients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a Phase I/II trial. Clin. Cancer Res. 12(11 Pt 1), 3416–3424 (2006).
  Medline CASGoogle Scholar
• 44 Elkord E, Dangoor A, Drury NL et al. An MVA-based vaccinetargeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J. Immunother. 31(9), 820–829 (2008).
  Medline CASGoogle Scholar
• 45 Morse MA, Chaudhry A, Gabitzsch ES et al. Novel adenoviral vector induces T-cell responses despiteanti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol. Immunother. 62(8), 1293–1301 (2013).
  Medline CASGoogle Scholar
• 46 Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agentanti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167–3175 (2010).
  Medline CASGoogle Scholar
• 47 Topalian SL, Hodi FS, Brahmer J et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455–2465 (2012).
  MedlineGoogle Scholar
• 48 Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372(26), 2509–2520 (2015). •• A study defining the role of immune checkpoint inhibitors in mCRC patients.
  Medline CASGoogle Scholar
• 49 Botta C, Bestoso E, Apollinari S et al. Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients. J. Immunother. 35(5), 440–447 (2012).
  Medline CASGoogle Scholar
• 50 Correale P, Botta C, Rotundo MS et al. Immune-boost with gemcitabine, oxaliplatin, levofolinate, 5-flurouracil, granulocyte/macrophage colony-stimulating-factor (GM-CSF) and aldesleukine (GOLFIG) enhances progression-free and overall-survival over FOLFOX chemotherapy in metastatic colorectal cancer patients: GOLFIG-2 multi-centric open label randomized Phase III trial. J. Immunotherapy. 37(1), 26–35 (2014). •• A study defining the antitumor efficacy of frontline GOLFIG chemoimmunotherapy over standard treatments in mCRC patients.
  Medline CASGoogle Scholar
• 51 Pozzi C, Cuomo A, Spadoni I et al. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. Nat. Med. 22(6), 624–631 (2016). • A preclinical study defining the immune-biological effects of cetuximab with potential antitumor activity in mCRC patients.
  Medline CASGoogle Scholar
• 52 Correale P, Cusi MG, Del Vecchio MT et al. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J. Immunol. 175(2), 820–828 (2005). •• A study defining the preclinical rationale for gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, GM-CFS, IL-2 (GOLFIG) chemoimmunotherapy in mCRC patients.
  Medline CASGoogle Scholar
• 53 Correale P, Cusi MG, Tsang KY et al. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J. Clin. Oncol. 23(35), 8950–8958 (2005). • A study defining the antitumor activity of GOLFIG chemoimmunotherapy in mCRC patients.
  Medline CASGoogle Scholar
• 54 Correale P, Tagliaferri P, Fioravanti A et al. Immunity feedback and clinical outcome in colon cancer patients undergoing chemo-immunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage-colony stimulating factor and aldesleukine (GOLFIG-1 trial). Clin. Cancer Res. 14(13), 4192–4199 (2008). • A study defining the role of autoimmunity in predicting the outcome of GOLFIG chemoimmunotherapy in mCRC patients.
  Medline CASGoogle Scholar
• 55 Correale P, Cusi MG, Tagliaferri P. Immunomodulatory properties of anticancer monoclonal antibodies: is the magic bullet’ still a reliable paradigm? Immunother. 3, 1–4 (2011). • An overview defining the immune-biological effects of monoclonal antibodies with potential antitumor activity in cancer patients.
  CASGoogle Scholar
• 56 Correale P, Botta C, Cusi MG et al. Cetuximab+/−chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int. J. Cancer. 130, 1577–1589 (2011). • A preclinical study defining the immune-biological effects of cetuximab with potential antitumor activity in mCRC patients.
  MedlineGoogle Scholar
• 57 Voena C, Chiarle R. Advances in cancer immunology and cancer immunotherapy. Discov. Med. 21(114), 125–133 (2016). •• A critical overview defining the recent advances in cancer immunotherapy.
  MedlineGoogle Scholar
• 58 Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J. Clin. Invest. 125(9), 3377–3383 (2015).
  MedlineGoogle Scholar
• 59 Blank CU. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Curr. Opin. Oncol. 26(2), 204–214 (2014).
  Medline CASGoogle Scholar
• 60 Bertrand A, Kostine M, Barnetche T et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 4(13), 211 (2015).
  Google Scholar
• 61 Chung KY, Gore I, Fong L et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J. Clin. Oncol. 28(21), 3485–3490 (2010).
  Medline CASGoogle Scholar
• 62 Shrimali RK, Janik JE, Abu-Eid R et al. Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Immunother. 7(7), 777–792 (2015).
  CASGoogle Scholar
• 63 Bonnet C, Beinse G, Cabel L et al. ESMO/ECCO 2015: the highlights of immunotherapy and targeted therapies. Bull. Cancer 103(6), 594–603 (2016). •• A critical overview defining the recent advances in cancer immunotherapy and immune checkpoint inhibitors.
  MedlineGoogle Scholar
• 64 Amin M, Lockhart AC. The potential role of immunotherapy to treat colorectal cancer. Expert. Opin. Investig. Drugs 24(3), 329–344 (2015).
  Medline CASGoogle Scholar
• 65 Kyi C, Postow MA. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunother. 8(7), 821–837 (2016). •• A critical overview defining the recent advances in cancer immunotherapy with immune checkpoint inhibitors.
  CASGoogle Scholar
• 66 He EY, Hawkins NJ, Mak G et al. The impact of mismatch repair status in colorectal cancer on the decision to treat with adjuvant chemotherapy: an Australian population-based multicenter study. Oncologist 21(5), 618–625 (2016).
  Medline CASGoogle Scholar
• 67 Mlecnik B, Bindea G, Angell HK et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 44(3), 698–711 (2016). •• A critical study defining the role in immunoscore in predicting the outcome of mCRC patients.
  Medline CASGoogle Scholar
• 68 Stojanovska V, Sakkal S, Nurgali K. Platinum-based chemotherapy: gastrointestinal immunomodulation and enteric nervous system toxicity. Am. J. Physiol. Gastrointest. Liver Physiol. 308(4), G223–G232 (2015).
  Medline CASGoogle Scholar
• 69 Takeuchi S, Baghdadi M, Tsuchikawa T et al. Chemotherapy-derived inflammatory responses accelerate the formation of immunosuppressive myeloid cells in the tissue microenvironment of human pancreatic cancer. Cancer Res. 75(13), 2629–2640 (2015).
  Medline CASGoogle Scholar
• 70 Leonard W, Dufait I, Schwarze JK et al. Myeloid-derived suppressor cells reveal radioprotective properties through arginase-induced l-arginine depletion. Radiother. Oncol. 119(2), 291–299 (2016).
  Medline CASGoogle Scholar
• 71 Wang D, An G, Xie S et al. The clinical and prognostic significance of CD14(+)HLA-DR (−/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy. Tumour Biol. 37(8), 10427–10433 (2016).
  Medline CASGoogle Scholar
• 72 Vatner RE, Formenti SC. Myeloid-derived cells in tumors: effects of radiation. Semin. Radiat. Oncol. 25(1), 18–27 (2015).
  MedlineGoogle Scholar
• 73 Pernot S, Terme M, Voron T et al. Colorectal cancer and immunity: what we know and perspectives. World J. Gastroenterol. 20(14), 3738–3750 (2014).
  MedlineGoogle Scholar
• 74 Galluzzi L, Buqué A, Kepp O et al. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 28(6), 690–714 (2015). •• A critical study defining the immunological effects of immunological effects of chemotherapy and targeted anticancer agents.
  Medline CASGoogle Scholar
• 75 Vacchelli E, Aranda F, Eggermont A et al. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology 3(1), e27878 (2014). • A study defining the immunological effects of immunological effects of chemotherapy.
  MedlineGoogle Scholar
• 76 Voron T, Marcheteau E, Pernot S et al. Control of the immune response by pro-angiogenic factors. Front. Oncol. 4, 70 (2014). • A study defining the immune-adjuvant effects of VEGF depletion.
  MedlineGoogle Scholar
• 77 Botta C, Misso G, Martino EC et al. The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response. Cell Death Dis. 7, e2299 (2016). • A study defining the immune-adjuvant effects of bevacizumab and its effect of tumor-associated inflammation.
  Medline CASGoogle Scholar
• 78 Adkins I, Fucikova J, Garg AD et al. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology 3(12), e968434 (2015). •• A critical study defining the immunological effects of radiotherapy.
  MedlineGoogle Scholar
• 79 Teng F, Kong L, Meng X et al. Radiotherapy combined with immune checkpoint blockade immunotherapy: achievements and challenges. Cancer Lett. 365(1), 23–29 (2015). • An overview defining the immunological effects of radiotherapy and future perspective.
  Medline CASGoogle Scholar
• 80 Chakraborty M, Abrams SI, Coleman N et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 64, 4328–4337 (2004).
  Medline CASGoogle Scholar